Tibet Cheezheng Tibetan Medicine Co., Ltd.
Symbool: 002287.SZ
SHZ
22.21
CNYMarktprijs vandaag
20.1008
Koers/Winst Verhouding
0.0000
Koers/Winst Groei Verhouding
11.78B
MRK Kapitalisatie
- 0.02%
DIV Rendement
Tibet Cheezheng Tibetan Medicine Co., Ltd. (002287-SZ) Jaarrekeningen
Balans
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 10005.55 | 2366.5 | 1976.9 | 1850.6 | ||||||||||||||||||
balance-sheet.row.short-term-investments | 8430.88 | 1963 | 1539.3 | 1184 | ||||||||||||||||||
balance-sheet.row.net-receivables | 3258.11 | 663.5 | 841.2 | 629.6 | ||||||||||||||||||
balance-sheet.row.inventory | 642.83 | 156.3 | 127.8 | 118.5 | ||||||||||||||||||
balance-sheet.row.other-current-assets | 87.71 | 8 | 246.6 | 337.7 | ||||||||||||||||||
balance-sheet.row.total-current-assets | 14048.36 | 3194.4 | 3192.4 | 2936.4 | ||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 5861.27 | 1651.6 | 1144.4 | 821.4 | ||||||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.intangible-assets | 1413.28 | 351.6 | 374.8 | 399.3 | ||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 1413.28 | 351.6 | 374.8 | 399.3 | ||||||||||||||||||
balance-sheet.row.long-term-investments | -561.9 | 1056.5 | -423.1 | -42.4 | ||||||||||||||||||
balance-sheet.row.tax-assets | 139.57 | 39.4 | 29.1 | 26.7 | ||||||||||||||||||
balance-sheet.row.other-non-current-assets | 5055.39 | 4.9 | 1568.9 | 1426.4 | ||||||||||||||||||
balance-sheet.row.total-non-current-assets | 11907.61 | 3104.1 | 2694.2 | 2631.4 | ||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.total-assets | 25955.97 | 6298.5 | 5886.6 | 5567.8 | ||||||||||||||||||
balance-sheet.row.account-payables | 744.05 | 255.6 | 93.5 | 184 | ||||||||||||||||||
balance-sheet.row.short-term-debt | 3466.68 | 478 | 762.3 | 610.8 | ||||||||||||||||||
balance-sheet.row.tax-payables | 237.12 | 55.6 | 61.9 | 37.7 | ||||||||||||||||||
balance-sheet.row.long-term-debt-total | 4253.1 | 1061.3 | 934.4 | 841.4 | ||||||||||||||||||
Deferred Revenue Non Current | 754.86 | 191.3 | 167 | 154.7 | ||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 127.94 | - | - | - | ||||||||||||||||||
balance-sheet.row.other-current-liab | 460.38 | 437.7 | 402.2 | 4.6 | ||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 4959.4 | 1089.2 | 1138.9 | 1039.4 | ||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 21.98 | 7 | 4.9 | 4.9 | ||||||||||||||||||
balance-sheet.row.total-liab | 11067.61 | 2334.4 | 2499 | 2347.4 | ||||||||||||||||||
balance-sheet.row.preferred-stock | 471.98 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.common-stock | 2120.75 | 530.2 | 530.2 | 530.3 | ||||||||||||||||||
balance-sheet.row.retained-earnings | 8154.57 | 2104.1 | 1784.8 | 1667 | ||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 2375.97 | 631.3 | 566.4 | 507.4 | ||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 1369.17 | 454.7 | 454.6 | 464.3 | ||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 14492.44 | 3720.3 | 3336 | 3169 | ||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 25955.97 | 6298.5 | 5886.6 | 5567.8 | ||||||||||||||||||
balance-sheet.row.minority-interest | 202.02 | 49.8 | 51.6 | 51.4 | ||||||||||||||||||
balance-sheet.row.total-equity | 14694.46 | 3770.1 | 3387.7 | 3220.4 | ||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 25955.97 | - | - | - | ||||||||||||||||||
Total Investments | 5660.63 | 3019.6 | 1116.2 | 1141.6 | ||||||||||||||||||
balance-sheet.row.total-debt | 7726.78 | 1546.3 | 1696.7 | 1452.2 | ||||||||||||||||||
balance-sheet.row.net-debt | 6152.1 | 1142.9 | 1259.1 | 785.6 |
Kasstroomoverzicht
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 585.9 | 581.2 | 469.5 | 710.8 | ||||||||||||||||||
cash-flows.row.depreciation-and-amortization | 7.51 | 95.8 | 83.2 | 65.8 | ||||||||||||||||||
cash-flows.row.deferred-income-tax | -17.2 | -24.3 | -8.3 | 38.8 | ||||||||||||||||||
cash-flows.row.stock-based-compensation | 0.87 | -168.3 | 3.6 | 4.9 | ||||||||||||||||||
cash-flows.row.change-in-working-capital | 38 | 47.8 | -374.7 | 521.1 | ||||||||||||||||||
cash-flows.row.account-receivables | 41.95 | 42 | -209.3 | 369.7 | ||||||||||||||||||
cash-flows.row.inventory | -28.46 | -28.5 | -10.6 | -24 | ||||||||||||||||||
cash-flows.row.account-payables | 0 | 9.8 | -146.4 | 136.6 | ||||||||||||||||||
cash-flows.row.other-working-capital | 24.51 | 24.5 | -8.3 | 38.8 | ||||||||||||||||||
cash-flows.row.other-non-cash-items | 320.18 | 439.6 | 112.5 | -306.5 | ||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 934.39 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -254.94 | -234.8 | -272.4 | -125.6 | ||||||||||||||||||
cash-flows.row.acquisitions-net | -0.56 | -0.6 | -3.8 | -61.1 | ||||||||||||||||||
cash-flows.row.purchases-of-investments | -1450 | -1492.4 | -1418 | -3494.7 | ||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 1063.16 | 1138.1 | 1355.9 | 1526 | ||||||||||||||||||
cash-flows.row.other-investing-activites | -229.98 | 0 | 3.8 | 0 | ||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -642.34 | -589.7 | -334.5 | -2155.4 | ||||||||||||||||||
cash-flows.row.debt-repayment | -1492.91 | -201.8 | -637.8 | -341.8 | ||||||||||||||||||
cash-flows.row.common-stock-issued | -250.46 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.common-stock-repurchased | -0.5 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.dividends-paid | -219.61 | -206.7 | -340.5 | -195.5 | ||||||||||||||||||
cash-flows.row.other-financing-activites | 1205.14 | -13.3 | 795.1 | 494.6 | ||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -92.13 | -431.9 | -183.2 | -42.8 | ||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 1.14 | 0.6 | 3 | -0.7 | ||||||||||||||||||
cash-flows.row.net-change-in-cash | 215.99 | -34.1 | -229.1 | -1164 | ||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 1573.63 | 403.4 | 437.6 | 666.6 | ||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 1357.64 | 437.6 | 666.6 | 1830.6 | ||||||||||||||||||
cash-flows.row.operating-cash-flow | 934.39 | 971.9 | 285.7 | 1034.9 | ||||||||||||||||||
cash-flows.row.capital-expenditure | -254.94 | -234.8 | -272.4 | -125.6 | ||||||||||||||||||
cash-flows.row.free-cash-flow | 679.46 | 737.1 | 13.3 | 909.3 |
Rij winst-en-verliesrekening
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 2101.04 | 2010.3 | 2044.8 | 1770.5 | ||||||||||||||||||
income-statement-row.row.cost-of-revenue | 349.53 | 382.4 | 324.1 | 265.3 | ||||||||||||||||||
income-statement-row.row.gross-profit | 1751.51 | 1627.9 | 1720.6 | 1505.1 | ||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||||||
income-statement-row.row.research-development | 58 | - | - | - | ||||||||||||||||||
income-statement-row.row.selling-general-administrative | 52.87 | - | - | - | ||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 1004.63 | - | - | - | ||||||||||||||||||
income-statement-row.row.other-expenses | -3.15 | 0.8 | 78 | 50.5 | ||||||||||||||||||
income-statement-row.row.operating-expenses | 1191.78 | 1161.6 | 1118.9 | 1007.3 | ||||||||||||||||||
income-statement-row.row.cost-and-expenses | 1541.31 | 1544 | 1443.1 | 1272.6 | ||||||||||||||||||
income-statement-row.row.interest-income | 10.54 | 13.1 | 17 | 34.4 | ||||||||||||||||||
income-statement-row.row.interest-expense | 63.33 | 63.1 | 56.4 | 53.4 | ||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 1004.63 | - | - | - | ||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 130.43 | 176.2 | -2.3 | -2.3 | ||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||||||
income-statement-row.row.other-operating-expenses | -3.15 | 0.8 | 78 | 50.5 | ||||||||||||||||||
income-statement-row.row.total-operating-expenses | 130.43 | 176.2 | -2.3 | -2.3 | ||||||||||||||||||
income-statement-row.row.interest-expense | 63.33 | 63.1 | 56.4 | 53.4 | ||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 61.27 | 95.8 | 143.9 | 111 | ||||||||||||||||||
income-statement-row.row.ebitda-caps | 598.17 | - | - | - | ||||||||||||||||||
income-statement-row.row.operating-income | 569.73 | 466.3 | 521.5 | 790.2 | ||||||||||||||||||
income-statement-row.row.income-before-tax | 672.15 | 642.5 | 519.2 | 787.9 | ||||||||||||||||||
income-statement-row.row.income-tax-expense | 73.04 | 65.2 | 49.7 | 77.1 | ||||||||||||||||||
income-statement-row.row.net-income | 585.9 | 581.2 | 472.5 | 715.9 |
Vaak gestelde vragen
Wat is Tibet Cheezheng Tibetan Medicine Co., Ltd. (002287.SZ) totale activa?
Tibet Cheezheng Tibetan Medicine Co., Ltd. (002287.SZ) totale activa is 6298478593.000.
Wat is de jaarlijkse omzet van de onderneming?
De jaarlijkse omzet is 1150739074.000.
Wat is de winstmarge van de onderneming?
De bedrijfswinstmarge is 0.834.
Wat is vrije kasstroom van de onderneming?
De vrije kasstroom is {free_cash_flow}}.
Wat is de nettowinstmarge van de onderneming?
De nettowinstmarge is 0.279.
Wat is de totale omzet van de onderneming?
De totale opbrengst is 0.271.
Wat is Tibet Cheezheng Tibetan Medicine Co., Ltd. (002287.SZ) nettowinst (netto-inkomen)?
De nettowinst is 581198850.000.
Wat is de totale schuld van het bedrijf?
De totale schuld is 1546314759.000.
Wat zijn de bedrijfskosten?
De bedrijfsuitgaven zijn 1161615874.000.
Wat is het kasstroomcijfer van het bedrijf?
Enretprise cash is 357241866.000.